Clorox (NYSE:CLX) Given New $134.00 Price Target at UBS Group

Clorox (NYSE:CLX - Get Free Report) had its price target decreased by research analysts at UBS Group from $150.00 to $134.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the stock. UBS Group's price objective points to a potential upside of 4.46% from the stock's current price.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley dropped their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company cut their target price on Clorox from $142.00 to $135.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 9th. JPMorgan Chase & Co. cut their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Citigroup reissued a "neutral" rating and issued a $135.00 target price (down previously from $140.00) on shares of Clorox in a research note on Tuesday. Finally, Evercore ISI set a $140.00 target price on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Clorox has an average rating of "Hold" and an average target price of $145.17.

Clorox Price Performance

Clorox stock traded down $0.98 on Thursday, reaching $128.28. The company's stock had a trading volume of 1,662,271 shares, compared to its average volume of 1,424,843. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The company has a market cap of $15.81 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 3.14 and a beta of 0.51. The business's fifty day moving average price is $127.49 and its 200 day moving average price is $141.59. Clorox has a twelve month low of $117.35 and a twelve month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company's revenue was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 EPS. Equities analysts expect that Clorox will post 7.15 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Pierre R. Breber acquired 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director owned 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Sonora Investment Management Group LLC grew its holdings in shares of Clorox by 2.5% during the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock worth $433,000 after buying an additional 72 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Clorox by 0.6% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock worth $1,953,000 after buying an additional 73 shares in the last quarter. Horizon Investments LLC boosted its position in Clorox by 4.4% during the first quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock valued at $258,000 after purchasing an additional 75 shares during the last quarter. Sfmg LLC boosted its position in Clorox by 2.8% during the first quarter. Sfmg LLC now owns 2,780 shares of the company's stock valued at $409,000 after purchasing an additional 76 shares during the last quarter. Finally, Hancock Whitney Corp boosted its position in Clorox by 4.3% during the first quarter. Hancock Whitney Corp now owns 2,064 shares of the company's stock valued at $304,000 after purchasing an additional 86 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.